Last Updated: 19 Sep 2024
Executive Summary
Elutia Inc. (ELUT) is a commercial-stage company developing drug-eluting biomatrix technology to enhance surgical outcomes. The company has a market capitalization of $139.99 million and trades on the NASDAQ exchange. The stock is currently trading at $3.86, below its 52-week high of $5.24 and above its 52-week low of $1.10.
Company Overview
Elutia Inc. is headquartered in Silver Spring, Maryland. The company's drug-eluting biomatrix technology is designed to deliver drugs directly to the surgical site, reducing the risk of infection and improving healing. Elutia's lead product, Eluvia, is a biomatrix that delivers vancomycin, an antibiotic, to the surgical site. Eluvia is approved for use in Europe and is in late-stage clinical trials in the United States.
Fundamental Analysis
Elutia Inc. has a trailing twelve-month revenue of $24.99 million and a gross profit of $19.22 million. The company's net loss for the trailing twelve months was $18.65 million, resulting in a loss per share of $3.09. Elutia has a book value of -$2.28 per share and a price-to-sales ratio of 5.6. The company's beta is 0.734.
Technical Analysis
The 50-day moving average of ELUT is $3.848, and the 200-day moving average is $3.372. The stock is currently trading above both its 50-day and 200-day moving averages. The relative strength index (RSI) is 52.41, indicating that the stock is neither overbought nor oversold.
Short Term Outlook
The short-term outlook for ELUT is mixed. The stock is trading above its 50-day and 200-day moving averages, which is a positive sign. However, the stock is also trading below its 52-week high, which is a negative sign. The RSI is neutral, indicating that the stock is not overbought or oversold.
Long Term Outlook
The long-term outlook for ELUT is positive. The company's drug-eluting biomatrix technology has the potential to revolutionize the way surgery is performed. If Eluvia is approved for use in the United States, it could become a major blockbuster drug.
Analyst Recommendations
Two analysts have issued buy ratings on ELUT, with an average target price of $10.00. No analysts have issued sell ratings on the stock.
